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CLINICAL GUIDELINES

American Society of Hematology living guidelines on the use of
anticoagulation for thromboprophylaxis for patients with COVID-19:
March 2022 update on the use of anticoagulation in critically ill patients
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Background: COVID-19–related critical illness is associated with an increased risk of venous
thromboembolism (VTE).
Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are
intended to support patients, clinicians, and other health care professionals in decisions about the
use of anticoagulation for patients with COVID-19.
Methods: ASH formed a multidisciplinary guideline panel, including 3 patient representatives, and
applied strategies to minimize potential bias from conﬂicts of interest. The McMaster University
Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre
supported the guideline development process, including performing systematic evidence reviews (up
to January 2022). The panel prioritized clinical questions and outcomes according to their
importance for clinicians and patients. The panel used the GRADE approach to assess evidence
and make recommendations, which were subject to public comment. This is an update to guidelines
published in February 2021 and May 2021 as part of the living phase of these guidelines.
Results: The panel made 1 additional recommendation: a conditional recommendation for the use
of prophylactic-intensity over therapeutic-intensity anticoagulation for patients with COVID19–related critical illness who do not have suspected or conﬁrmed VTE. The panel emphasized the
need for an individualized assessment of thrombotic and bleeding risk.

Submitted 25 April 2022; accepted 13 June 2022; prepublished online on Blood
Advances First Edition 24 June 2022; ﬁnal version published online 29 August 2022.
DOI 10.1182/bloodadvances.2022007940.
*A.C. and E.K.T. contributed equally to this study.

© 2022 by The American Society of Hematology. Licensed under Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NCND 4.0), permitting only noncommercial, nonderivative use with attribution. All other
rights reserved.

The evidence proﬁle and evidence-to-decision table are included via a link in the text.
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Conclusions: This conditional recommendation was based on very low certainty in the evidence,
underscoring the need for additional, high-quality, randomized controlled trials comparing different
intensities of anticoagulation for patients with COVID-19–related critical illness.

Summary of recommendations
Recommendation 1b

Remarks:
 Patients with COVID-19–related critical illness are deﬁned as
those suffering from an immediately life-threatening condition
who would typically be admitted to an intensive care unit (ICU).
Examples include patients requiring hemodynamic support, ventilatory support, and renal replacement therapy.
 A separate recommendation (1a) addresses the comparison of
intermediate-intensity and prophylactic-intensity anticoagulation
in critically ill patients with COVID-19.

Introduction
There is a high incidence of thrombotic complications in critically ill
patients with COVID-19. Earlier in the pandemic, VTE was reported
in up to 22.7% of such patients despite the use of standard thromboprophylaxis.1 Thrombosis of the microvasculature contributes to
other complications of COVID-19 including respiratory failure and
death. At the same time, higher-intensity anticoagulation is associated with an increased risk of bleeding among hospitalized patients
with COVID-19.2 Consequently, there has been strong interest in
establishing whether intensiﬁed anticoagulant regimens improve
outcomes.

hemorrhage, ischemic stroke, ST-elevation myocardial infarction,
multiple organ failure, limb amputation, invasive mechanical ventilation, ICU admission, and length of hospitalization as critical outcomes and placed a high value on reducing these outcomes with
the interventions assessed.
 Panel members noted that there was possible uncertainty and
variability in the relative value that patients place on avoiding
major bleeding events compared with reducing thrombotic
events.

These guidelines are based on systematic reviews of evidence conducted under the direction of the McMaster University Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) Centre with international collaborators. This is an update
on the previous American Society of Hematology (ASH) guideline
published in May 2021,3 and focuses on the role of anticoagulation
for patients with COVID-19–related critical illness. The panel followed best practice for guideline development recommended by
the Institute of Medicine and the Guidelines International Network.4-6 The panel used the GRADE approach7-13 to assess the
certainty of the evidence and formulate recommendations. The recommendation is listed in Table 1.

Explanations and other considerations

Values and preferences
 The guideline panel identiﬁed all-cause mortality, pulmonary embolism (PE), deep vein thrombosis (DVT), major bleeding, intracranial

Please refer to the original ASH guideline on thromboprophylaxis for
patients with COVID-19.3 All recommendations and updates to
these living guidelines are accessible at the ASH COVID-19 anticoagulation webpage.14
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Please refer to the original ASH guideline on thromboprophylaxis for
patients with COVID-19.3

Interpretation of strong and conditional
recommendations
Please refer to the original ASH guideline on thromboprophylaxis for
patients with COVID-19.3

Aims of these guidelines and specific objectives

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/6/17/4975/1917319/advancesadv2022007940.pdf by guest on 28 September 2022

The ASH guideline panel suggests using prophylactic-intensity
over therapeutic-intensity anticoagulation for patients with
COVID-19–related critical illness who do not have suspected
or conﬁrmed venous thromboembolism (VTE; conditional recommendation based on very low certainty in the evidence about
effects ⨁
).

 An individualized assessment of the patient’s risk of thrombosis
and bleeding is important when deciding on anticoagulation
intensity. Risk assessment models to estimate thrombotic risk
have been validated in hospitalized patients with COVID-19
(critically or noncritically ill), with modest prognostic performance. No risk assessment models for bleeding have
been validated for patients with COVID-19. The panel acknowledges that higher-intensity anticoagulation may be preferred
for patients judged to be at low bleeding risk and high
thrombotic risk.
 At present, there is no direct high-certainty evidence comparing
different types of anticoagulants for patients with COVID-19.
Unfractionated or low-molecular-weight heparin was used in the
identiﬁed studies.
 This recommendation does not apply to patients who
require anticoagulation to prevent thrombosis of extracorporeal circuits such as those on extracorporeal membrane oxygenation or continuous renal replacement therapy.

Table 1. Recommendations
Recommendation

Remarks

Recommendation 1b. The ASH guideline panel suggests using
prophylactic-intensity over therapeutic-intensity anticoagulation
for patients with COVID-19–related critical illness who do not
have suspected or conﬁrmed VTE (conditional recommendation
based on very low certainty in the evidence about effects
).
⨁

Description of the health problem
The COVID-19 pandemic has had a signiﬁcant public health impact.
As of 5 March 2022, more than 445 million cases and nearly
6 million deaths had been attributed to COVID-19–related illness
globally.15 Thrombosis has emerged as an important complication
of patients hospitalized with COVID-19–related critical illness, with
VTE occurring in up to 22.7% of such patients, often despite the
use of standard thromboprophylaxis.1 Moreover, microvascular
thrombosis associated with COVID-19 may contribute to other
adverse outcomes including respiratory failure and death.16
Previously published ASH guidelines issued a conditional recommendation in favor of prophylactic-intensity rather than higherintensity anticoagulation for patients with COVID-19–related critical
illness without suspected or conﬁrmed VTE.3 Those recommendations were based on very low certainty evidence derived exclusively
from observational studies. Since then, 2 randomized controlled trials (RCTs) comparing therapeutic-intensity vs prophylactic-intensity
anticoagulation for patients with COVID-19–related critical illness
have been reported.17,18 This living guideline update incorporates
evidence from these RCTs to address the role of therapeuticintensity vs prophylactic-intensity anticoagulation for patients with
COVID-19–related critical illness.

Description of the target populations
The target population, patients with COVID-19–related critical illness, is described in Table 2.

Methods
This updated guideline recommendation on the use of therapeuticintensity anticoagulation in critically ill patients was developed in the
living phase of the ASH living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19. The ASH
guideline panel generated recommendation 1b on January 2022
before soliciting public comments.
Table 2. Deﬁnition of target population
Target population
Critically ill

Definition
Patients with COVID-19 who develop respiratory or
cardiovascular failure normally requiring advanced clinical
support in the ICU or CCU but could include admission
to another department if the ICU/CCU was over capacity.
ICU/CCU capacity could vary according to the speciﬁc
setting.
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We followed the same methods as published in the initial guideline,3
with the following important updates and differences for the recommendation reported here:
 Guideline funding and management of conﬂicts of interest: supplemental File 4 provides updated “Participant Information
Forms” for all panel members, detailing ﬁnancial and nonﬁnancial
interests, as well as the ASH conﬂict of interest policies agreed
to by each individual. Supplemental File 5 provides the updated
complete participant information forms of researchers on the
systematic review team who contributed to these guidelines.
 Formulating speciﬁc clinical questions and determining outcomes of interest: this updated manuscript focuses on 1 question: In patients with COVID-19–related critical illness who do
not have conﬁrmed or suspected VTE, should we use direct oral
anticoagulants, low-molecular-weight heparin, unfractionated
heparin, fondaparinux, argatroban, or bivalirudin at therapeutic
intensity vs prophylactic intensity? There were no changes in the
deﬁnitions for population (Table 2), anticoagulation intensity, or
outcomes.3
 Evidence review and development of the recommendation: a
new evidence-to-decision framework was created for recommendation 1b (see Recommendations) using any applicable evidence and information from the evidence-to-decision (EtD)
framework for the initial recommendation 17 and updated with
new evidence and considerations speciﬁcally for recommendation 1b. The systematic review to identify comparative antithrombotic studies for the entire guideline was updated until 24
January 2022, the literature search strategy (supplemental File
6) was modiﬁed only to add search terms for antiplatelet agents
for another guideline question, and the protocol (supplemental
File 9) was modiﬁed to focus on inclusion of only RCTs for the
guideline after the initial phase. Baseline risk estimates for outcomes for patients with COVID-19–related critical illness were
updated with observational evidence until 27 July 2021 and
prophylactic-intensity anticoagulation event rates from RCTs
until 24 January 2022. The decision to create this updated
guideline recommendation was based on publication of 2
RCTs,17,18 which were critically assessed by the evidence synthesis team and determined to increase the certainty of the evidence for critical outcomes. Decision thresholds were obtained
for each critical outcome (Table 3) to support judgements about
whether the magnitude of an effect estimate was trivial, small,
moderate, or large, as well as for determining imprecision of the
effect estimate. Thresholds were calculated using the outcomeASH GUIDELINES ON ANTICOAGULATION IN COVID-19 4977
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 Patients with COVID-19–related critical illness are deﬁned as those suffering from an immediately lifethreatening condition who would typically be admitted to an ICU. Examples include patients requiring
hemodynamic support, ventilatory support, and renal replacement therapy.
 A separate recommendation (1a) addresses the comparison of intermediate-intensity and prophylacticintensity anticoagulation in critically ill patients with COVID-19.
 An individualized assessment of the patient’s risk of thrombosis and bleeding is important when deciding on
anticoagulation intensity. Risk assessment models to estimate thrombotic risk in hospitalized patients have
been validated in patients with COVID-19 (critically or noncritically ill), with modest prognostic performance.
No risk assessment models for bleeding have been validated in patients with COVID-19. The panel
acknowledges that higher-intensity anticoagulation may be preferred for patients judged to be at low
bleeding risk and high thrombotic risk.
 At present, there is no direct high-certainty evidence comparing different types of anticoagulants for patients
with COVID-19. Unfractionated or low-molecular-weight heparin was used in identiﬁed studies.
 This recommendation does not apply to patients who require anticoagulation to prevent thrombosis of
extracorporeal circuits such as extracorporeal membrane oxygenation or continuous renal replacement therapy.

Table 3. Decision thresholds per critical outcome
Decision thresholds (events per 1000; 95% CI)
Outcome
Mortality

Utility value,mean (SD)

Trivial/small

Small/moderate

Moderate/large

16 (9 to 22)

31 (22 to 39)

60 (46 to 73)

0.42 (0.15)

27 (15 to 38)

53 (38 to 68)

103 (80 to 125)

Proximal DVT, moderate

0.58 (0.14)

37 (21 to 53)

73 (53 to 94)

142 (110 to 173)

Major bleeding

0.33 (0.23)

23 (13 to 33)

46 (33 to 59)

89 (69 to 109)

Ischemic stroke, severe

0.14 (0.10)

18 (10 to 26)

36 (26 to 46)

69 (54 to 85)

Intracranial hemorrhage

0.12 (0.10)

18 (10 to 25)

35 (25 to 45)

68 (53 to 83)

Multiple organ failure

0.15 (0.14)

18 (10 to 26)

36 (26 to 46)

70 (54 to 86)

ST-elevation MI (STEMI)

0.31 (0.19)

23 (13 to 32)

44 (32 to 57)

86 (67 to 105)

Limb amputation

0.26 (0.16)

21 (12 to 30)

41 (30 to 53)

80 (63 to 98)

Long-term invasive ventilation

0.20 (0.12)

20 (11 to 28)

38 (28 to 49)

74 (58 to 91)

speciﬁc utility value and results from a decision threshold survey
that included the members of this panel.
 Finally, for all outcomes, we report pooled effect estimates
based on unadjusted effects from all trials. Because one adaptive multiplatform trial reported adjusted effect estimates for certain outcomes,18 we performed sensitivity analyses by pooling
their adjusted effects with the unadjusted effects of the remaining trials to determine whether the results remained similar (see
the footnotes of the evidence proﬁle).
 Document review: the initial draft recommendation was
reviewed by all members of the panel and made available
online from 7 March to 14 March 2022 for external review by
stakeholders including allied organizations, other medical professionals, patients, and the public. As part of the public comment, there were 444 views; 1 individual or organization
submitted a response that did not require changes to the document. On 11 April 2022, the ASH Guideline Oversight Subcommittee and the ASH Committee on Quality approved that
the deﬁned guideline development process was followed, and
on 13 April 2022, the ofﬁcers of the ASH Executive Committee approved submission of the updated guideline manuscript
for publication under the imprimatur of ASH. The updated
guideline manuscript was then subjected to peer review by
Blood Advances.
 How to use these guidelines: we refer readers to the description
in the initial guideline publication from February 20213 and the
user guide to ASH clinical practice guidelines.19

or conﬁrmed VTE (conditional recommendation based on very
low certainty in the evidence about effects ⨁
).
Remarks
 Patients with COVID-19–related critical illness are deﬁned as








those suffering from an immediately life-threatening condition
who would typically be admitted to an ICU. Examples include
patients requiring hemodynamic support, ventilatory support,
and renal replacement therapy.
A separate recommendation (1a) addresses the comparison of
intermediate-intensity and prophylactic-intensity anticoagulation
in critically ill patients with COVID-19.
An individualized assessment of the patient’s risk of thrombosis
and bleeding is important when deciding on anticoagulation
intensity. Risk assessment models to estimate thrombotic risk
have been validated in hospitalized patients with COVID-19
(critically or noncritically ill), with modest prognostic performance. No risk assessment models for bleeding have been validated for patients with COVID-19. The panel acknowledges that
higher-intensity anticoagulation may be preferred for patients
judged to be at low bleeding risk and high thrombotic risk.
At present, there is no direct high-certainty evidence comparing
different types of anticoagulants for patients with COVID-19.
Unfractionated or low-molecular-weight heparin was used in the
identiﬁed studies.
This recommendation does not apply to patients who require
anticoagulation to prevent thrombosis of extracorporeal circuits
such as those on extracorporeal membrane oxygenation or
continuous renal replacement therapy.

Recommendations
Recommendation 1b
Should direct oral anticoagulants, low-molecular-weight heparin,
unfractionated heparin, fondaparinux, argatroban, or bivalirudin be
prescribed at therapeutic intensity or prophylactic intensity for
patients with COVID-19–related critical illness who do not have
suspected or conﬁrmed VTE?

Recommendation 1b
The ASH guideline panel suggests using prophylactic-intensity
over therapeutic-intensity anticoagulation for patients with
COVID-19–related critical illness who do not have suspected
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Summary of the evidence. We rated the certainty in the evidence as very low for all critical outcomes, mainly owing to serious
indirectness and very to extremely serious imprecision (see evidence
proﬁle and EtD framework online at https://guidelines.ash.gradepro.
org/proﬁle/W_BGvwzgPU0).
We found several systematic reviews of randomized controlled trials
that addressed this question, either speciﬁcally or as part of a larger
systematic review on anticoagulation for patients with COVID-19.20
None of these systematic reviews reported a summary of ﬁndings
table or evidence proﬁle, with certainty of the evidence assessment,
for all critical outcomes prioritized for this recommendation. The living systematic review informing all recommendations for the ASH
13 SEPTEMBER 2022 • VOLUME 6, NUMBER 17
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0

PE, moderate

living guidelines since June 2020 provided the evidence for the evidence proﬁle and EtD framework. Supplemental File 10 presents
the characteristics of the included studies.

Benefits. Based on the panel’s thresholds for effect sizes (Table
3), therapeutic-intensity anticoagulation may reduce pulmonary
embolism with 52 fewer (95% conﬁdence interval [CI]: 65 fewer to
30 fewer) cases per 1000 patients (odds ratio [OR]: 0.33; 95% CI:
0.18-0.60), may have little to no effect on deep venous thrombosis
with 5 fewer (95% CI: 25 fewer to 37 more) cases per 1000
patients (OR: 0.86, 95% CI: 0.37-2.01), may have little to no effect
on ischemic stroke with 1 fewer (95% CI: 8 fewer to 17 more)
cases per 1000 patients (OR: 0.94, 95% CI: 0.36-2.45), and may
have little to no effect on ST-elevation myocardial infarction with 1
fewer (95% CI: 2 fewer to 3 more) cases per 1000 patients (OR:
0.73, 95% CI: 0.28-1.94), but the evidence is very uncertain for all
outcomes (very low certainty).
Harms and burden. Based on the panel’s thresholds for effect
sizes (Table 3), therapeutic-intensity anticoagulation may increase
all-cause mortality with 11 more (95% CI: 30 fewer to 59 more)
cases per 1000 patients (OR: 1.06; 95% CI: 0.84-1.35), may
increase major bleeding with 22 more (95% CI: 6 fewer to 87
more) cases per 1000 patients (OR: 1.95; 95% CI: 0.75-5.09),
may increase multiple organ failure with 108 more (95% CI: 38
fewer to 470 more) cases per 1000 patients (OR: 2.68; 95% CI:
0.50-14.18), may have little to no effect on intracranial hemorrhage
with no events observed in the trials, may increase invasive mechanical ventilation with 35 more (95% CI: 120 fewer to 281 more)
cases per 1000 patients (OR: 1.21; 95% CI: 0.41-3.51), may
increase limb amputation with 10 more (95% CI: 2 fewer to 219
more) cases per 1000 patients (OR: 4.43; 95% CI: 0.21-95.06),
and may increase length of admission with 2 more (95% CI: 0.44
more to 3.56 more) days, but the evidence is very uncertain for all
outcomes (very low certainty).

Conclusions for this recommendation. The use of decision
thresholds (Table 3) allowed the panel to quantify the magnitude of
effect per outcome to come to an overall judgement on the balance
of health effects. In terms of desirable effects, although there was a
suggestion of a small reduction in PE with therapeutic-intensity anticoagulation, this evidence was of very low certainty. Meanwhile,
trivial-to-moderate harms were observed for multiple other critical
outcomes including mortality, major bleeding, invasive mechanical
ventilation, multiple organ failure, and limb amputation, some of
which were felt to be independent. Taken together, the panel
judged the aggregate harm of the intervention to be moderate, albeit
based on very low certainty in the evidence.
These moderate harms were felt to outweigh the small beneﬁts of
therapeutic-intensity anticoagulation, and therefore prophylacticintensity anticoagulation was suggested. The panel acknowledged
that an individualized decision based on each patient’s thrombotic
and bleeding risk is important.

What are others saying and what is new in
these guidelines?
Numerous national and international organizations have published
clinical practice guidelines or guidance documents on the role of anticoagulation in hospitalized, critically ill COVID-19 patients. Among
those published or updated since 2021, the year that RCTs comparing different intensities of anticoagulation were ﬁrst published, both
the Japanese living guidelines on drug management for COVID-1923
and the European Respiratory Society living guidelines24 recommend
anticoagulation for patients with COVID-19–related critical illness but
do not specify an intensity. By contrast, the French guideline25 suggests that patients with severe COVID-19 (oxygen requirement
greater than 6 L/min or mechanical ventilation) should receive at least
intermediate-dose prophylactic anticoagulation, although these guidelines were written before the publication of the multiplatform18 and
INSPIRATION26 randomized trials. The US National Institutes of
Health COVID-19 Treatment Guideline, the World Health Organization Living Guidance document, and draft guidelines from the International Society on Thrombosis and Haemostasis recommend that
patients who require ICU-level care should receive standard
prophylactic-intensity (rather than intermediate- or therapeuticintensity) anticoagulation as VTE prophylaxis.27-29
Major differences between the ASH guidelines and these other
documents include use of high-quality systematic reviews and EtD
frameworks, marker states to estimate the relative importance of key
outcomes to patients, and decision thresholds to facilitate judgments about the magnitude of desirable and undesirable effects.

Other EtD criteria and considerations. The guideline panel
noted that there was possible uncertainty and variability in the relative value patients place on reducing thrombotic events compared
with avoiding major bleeding events. The panel agreed that the use
of prophylactic-intensity anticoagulation would be acceptable to
patients and health care providers. However, given the low certainty
in the evidence for some outcomes, there may be regional variation
in the acceptability of therapeutic-intensity anticoagulation, particularly in regions where baseline VTE risk may be lower (eg, Asian
populations).21,22 In addition, the panel noted possible racial and
ethnic disparity in clinical trial enrollment. However, the intervention

The limitations of these guidelines are inherent in the very low certainty of the evidence we identiﬁed for the research question. In
addition, dramatic changes have occurred over the course of the
pandemic with respect to circulating viral variants, the affected
patient population, and the use of treatments other than anticoagulants for management of COVID-19–related critical illness (eg, antiviral agents, corticosteroids, Janus kinase inhibitors, interleukin-6
inhibitors). Much of the evidence included in our systematic review
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Two RCTs reported the effect of therapeutic-intensity anticoagulation in critically ill patients with COVID-19.17,18 In the publication, or
by providing unpublished data, both trials reported results for allcause mortality, PE, DVT, major bleeding, ischemic stroke, and
ST-elevation myocardial infarction. One trial provided results for multiple organ failure, intracranial hemorrhage, limb amputation, invasive
mechanical ventilation, and length of hospital admission. The authors
of 1 RCT provided unpublished data for patients in the ICU separately.17 In accordance with the GRADE approach, the overall certainty of the evidence of effects was very low based on the lowest
certainty among critical outcomes.

was not felt to have a differential impact on health equity relative to
the comparison.

was collected earlier in the pandemic and may not fully reﬂect baseline risk or the impact of different intensities of anticoagulation in the
current phase of the pandemic.

Plans for updating these guidelines
Our recommendations will continue to be updated based on living
reviews of evolving evidence. Our methods of living systematic
reviews and recommendations, including criteria for deciding when to
reassess and update recommendations, are described elsewhere.3

Adaptation of these guidelines will be necessary in many circumstances. These adaptations should be based on the associated EtD
frameworks.11

Priorities for research
Based on gaps in evidence identiﬁed during the guideline development process, the panel identiﬁed the following research priorities:
 Studies assessing baseline VTE risk, major bleeding risk, and
mortality in critically ill patients receiving prophylactic-intensity
anticoagulation therapy and how these risks have varied over the
course of the pandemic
 Additional large, high-quality RCTs comparing therapeuticintensity with prophylactic-intensity anticoagulation for patients
with COVID-19–associated critical illness, as the current evidence of effects is of very low certainty
 Studies examining the impact of non-anticoagulant interventions
(eg, vaccines, corticosteroids, antiviral therapies, anticytokine
therapies, monoclonal antibody therapies) on thrombotic risk
 Studies examining the impact of different viral variants on thrombotic risk
 Development and validation of risk assessment models for
thrombosis and bleeding for patients with COVID-19–related
critical illness
 Studies examining the impact of anticoagulant therapy on thrombosis and bleeding outcomes for patients of differing race/
ethnicity
 Studies comparing mortality, thrombosis, bleeding, and functional outcomes with different available anticoagulant agents
and intensities
 Studies estimating the relative disutility of thrombotic and bleeding outcomes for patients with COVID-19–related critical illness
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